Patients receiving ponsegromab experienced significantly greater weight gain and physical activity than those receiving placebo.

Another breakthrough has been antibody–drug conjugates. Last year, two antibody–drug conjugates received full FDA approval, telisotuzumab vedotin in cervical cancer and rituximab and tancine tissue ...

潜在“first-in-class”抗体偶联药物telisotuzumab vedotin有望获批治疗c-Met蛋白过度表达的经治局部晚期或转移性非鳞状NSCLC成人患者。 诺和诺德（Novo Nordisk ...

News of the ImmunoGen play comes shortly after the company reported new clinical results for telisotuzumab vedotin (Teliso-V) ADC in patients with relapsed or refractory non-squamous, non-small ...

Spread betting business IG Group returned to the market in April 2005, two years after being bought up by private equity firm CVC Capital for just £143m. The core business is spread betting ...